UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline
Painful Skin Abscesses, Myasthenia Gravis And Refractory Epilepsy Targeted
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
You may also be interested in...
The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.